Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CVS · NYSE · United States · Retail-Drug Stores And Proprietary Stores
In shortCVS HEALTH Corp is profitable, generates cash and carries moderate debt, with revenue growing (+7.8% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 1.2% | 21/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 0.4% | 22/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 2.3% | 12/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 2.7% | 18/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 0.84× | 4/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.86× | 63/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 5.82× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 1.49× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 0.99 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 1.9% | 28/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 4.42× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 2.7% | 100/100 |
| Operating margin volatility | 1.3% | 97/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 7.6% | 59/100 |
|---|---|---|
| EPS growth, 3-year average | -24.7% | 0/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 292,111 | 322,467 | 357,776 | 372,809 | 402,067 |
| Cost of revenue | 175,803 | 196,892 | 217,098 | 206,287 | 221,167 |
| Gross profit | 116,308 | 125,575 | 140,678 | 166,522 | 180,900 |
| Operating income | 13,310 | 7,954 | 13,743 | 8,516 | 4,660 |
| Interest expense | 2,503 | 2,287 | 2,658 | 2,958 | 3,119 |
| Pre-tax income | 10,537 | 5,836 | 11,173 | 6,148 | 2,136 |
| Income tax | 2,548 | 1,509 | 2,805 | 1,562 | 408 |
| Net income | 8,001 | 4,311 | 8,344 | 4,614 | 1,768 |
| Diluted EPS | $6.02 | $3.26 | $6.47 | $3.66 | $1.39 |
| Diluted shares (millions) | 1,329 | 1,323 | 1,290 | 1,262 | 1,271 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
0.99 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 5, 2026